MedTrace Logo

Treatment of Mycobacterium Xenopi Pulmonary Infection

NCT01298336 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2025-11-19

No results posted yet for this study

Summary

The purpose of this study is to determine the 6-months sputum conversion rate with a clarithromycin or moxifloxacin containing regimen in patients with a M. xenopi pulmonary infection.

Conditions

  • Atypical; Mycobacterium, Pulmonary, Tuberculous

Interventions

DRUG

Clarithromycin

500 mg twice a day seven days a week

DRUG

Moxifloxacin

400 mg per day seven days a week

Sponsors & Collaborators

  • Centre Hospitalier Universitaire, Amiens

    lead OTHER

Principal Investigators

  • Claire ANDREJAK, Dr · Centre Hospitalier Universitaire, Amiens

  • Claire ANDREJAK, MD · CHU Amiens

  • Vincent JOUNIEAUX, MD PhD · CHU Amiens

  • Nicolas VEZIRIS, MD-PhD · APHP Pitie Salpetriere Hospital, National Center Of Mycobacteria

  • Jacques CADRANEL, MD PhD · Tenon Hospital APHP Paris

  • Francois-Xavier LESCURE, MD · Tenon hospital APHP Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-02
Primary Completion
2019-03-31
Completion
2019-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01298336 on ClinicalTrials.gov